CA2361736A1 - Psp 94: use for treatment of hypercalcemia and bone metastasis - Google Patents

Psp 94: use for treatment of hypercalcemia and bone metastasis Download PDF

Info

Publication number
CA2361736A1
CA2361736A1 CA002361736A CA2361736A CA2361736A1 CA 2361736 A1 CA2361736 A1 CA 2361736A1 CA 002361736 A CA002361736 A CA 002361736A CA 2361736 A CA2361736 A CA 2361736A CA 2361736 A1 CA2361736 A1 CA 2361736A1
Authority
CA
Canada
Prior art keywords
polypeptide
psp
group
analog
pck3145
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361736A
Other languages
English (en)
French (fr)
Inventor
Unknown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Procyon Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procyon Biopharma Inc filed Critical Procyon Biopharma Inc
Priority to CA002361736A priority Critical patent/CA2361736A1/en
Priority to EP02774221A priority patent/EP1441756A1/en
Priority to JP2003541867A priority patent/JP2005513000A/ja
Priority to CA002407548A priority patent/CA2407548A1/en
Priority to US10/291,360 priority patent/US20030119744A1/en
Priority to PCT/CA2002/001737 priority patent/WO2003039576A1/en
Priority to AU2002340681A priority patent/AU2002340681B2/en
Publication of CA2361736A1 publication Critical patent/CA2361736A1/en
Priority to US10/857,358 priority patent/US20050026833A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
CA002361736A 2001-11-08 2001-11-08 Psp 94: use for treatment of hypercalcemia and bone metastasis Abandoned CA2361736A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002361736A CA2361736A1 (en) 2001-11-08 2001-11-08 Psp 94: use for treatment of hypercalcemia and bone metastasis
EP02774221A EP1441756A1 (en) 2001-11-08 2002-11-08 Psp-94: use for treatment of hypercalcemia and bone metastasis
JP2003541867A JP2005513000A (ja) 2001-11-08 2002-11-08 Ｐｓｐ−９４：高カルシウム血症及び骨転移の治療のための使用
CA002407548A CA2407548A1 (en) 2001-11-08 2002-11-08 Psp94: use for treatment of hypercalcemia and bone metastasis
US10/291,360 US20030119744A1 (en) 2001-11-08 2002-11-08 PSP-94: use for treatment of hypercalcemia and bone metastasis
PCT/CA2002/001737 WO2003039576A1 (en) 2001-11-08 2002-11-08 Psp-94: use for treatment of hypercalcemia and bone metastasis
AU2002340681A AU2002340681B2 (en) 2001-11-08 2002-11-08 PSP-94: Use for treatment of hypercalcemia and bone metastasis
US10/857,358 US20050026833A1 (en) 2001-11-08 2004-06-01 PSP-94: use for treatment of hypercalcemia and bone metastasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002361736A CA2361736A1 (en) 2001-11-08 2001-11-08 Psp 94: use for treatment of hypercalcemia and bone metastasis

Publications (1)

Publication Number Publication Date
CA2361736A1 true CA2361736A1 (en) 2003-05-08

Family

ID=4170464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361736A Abandoned CA2361736A1 (en) 2001-11-08 2001-11-08 Psp 94: use for treatment of hypercalcemia and bone metastasis

Country Status (6)

Country Link
US (1) US20030119744A1 (https=)
EP (1) EP1441756A1 (https=)
JP (1) JP2005513000A (https=)
AU (1) AU2002340681B2 (https=)
CA (1) CA2361736A1 (https=)
WO (1) WO2003039576A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148514A1 (en) * 2003-09-26 2005-07-07 Panchal Chandra J. Method and composition for treatment of angiogenesis
CA2441695A1 (en) * 2003-09-26 2005-03-26 Unknown Regulation of matrix metalloproteinases by psp94 family members
JP2008501645A (ja) * 2004-06-01 2008-01-24 アンブリリア・バイオファーマ・インコーポレーテッド 血管新生を治療し、癌の進行および転移を予防するための方法、ならびにそのための前立腺分泌タンパク質（ｐｓｐ９４）ファミリーメンバーを含む組成物
CA2502479A1 (en) * 2004-12-01 2006-06-01 Procyon Biopharma Inc. Laminin receptor binding molecule
JP2022536222A (ja) * 2018-11-02 2022-08-15 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428011A (en) * 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
CA2355334A1 (en) * 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
US20050026833A1 (en) * 2001-11-08 2005-02-03 Rabbani Shafaat Ahmed PSP-94: use for treatment of hypercalcemia and bone metastasis

Also Published As

Publication number Publication date
JP2005513000A (ja) 2005-05-12
WO2003039576A1 (en) 2003-05-15
AU2002340681B2 (en) 2007-09-13
US20030119744A1 (en) 2003-06-26
EP1441756A1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
US8551951B2 (en) Pharmaceutical preparations and methods for inhibiting tumors
EP2913057B1 (en) Cancer peptide therapeutics
US20190388504A1 (en) Capcna peptide therapeutics for cancer
CA2614687A1 (en) Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
JP2012529272A (ja) Ｇｄｎｆおよびｂｄｎｆを中枢神経系へ送達するための融合タンパク質
AU2002213691A1 (en) Pharmaceutical preparations and methods for inhibiting tumors
WO1997040156B1 (en) Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
CA2718949C (en) Peptide compositions for cancer treatment
CA2361736A1 (en) Psp 94: use for treatment of hypercalcemia and bone metastasis
AU2002340681A1 (en) PSP-94: Use for treatment of hypercalcemia and bone metastasis
US20050026833A1 (en) PSP-94: use for treatment of hypercalcemia and bone metastasis
US12173061B2 (en) Compositions and methods for treatment of chronic lung diseases
AU2007246192A1 (en) PSP-94: use for treatment of hypercalcemia and bone metastasis
ES2351783T3 (es) Preparaciones farmacéuticas y procedimientos para la inhibición de tumores.
CA2407548A1 (en) Psp94: use for treatment of hypercalcemia and bone metastasis
CA2488777A1 (en) Laminin receptor binding molecule
EP1678207A1 (en) Regulation of matrix metalloproteinases by psp94 family members
WO2003093787A2 (en) Antiproliferative protein from hypericum perforatum and nucleic acids encoding the same
HK1214177B (en) Cancer peptide therapeutics
WO2006058431A1 (en) Laminin receptor binding molecule
CA2591301A1 (en) Laminin receptor binding molecule
WO2003072031A2 (en) Treatment of disease by inducing cell apoptosis
AU2007249137A1 (en) Pharmaceutical preparations and methods for inhibiting tumors

Legal Events

Date Code Title Description
FZDE Discontinued